1-4 of 4
Parag Garhyan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39: 1241–1249

Christof M. Kazda, Ying Ding, Ronan P. Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E. Watson, Andrew J. Lewin, William H. Landschulz, Mark A. Deeg, David E. Moller, Thomas A. Hardy
Journal: Diabetes Care
Diabetes Care 2017;40(6):808
https://doi.org/10.2337/dc17-er06
Published: 18 April 2017
View articletitled, Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39: 1241–1249
Open the PDF for Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39: 1241–1249 in another window
Journal Articles

Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249

Christof M. Kazda, Ying Ding, Ronan P. Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E. Watson, Andrew J. Lewin, William H. Landschulz, Mark A. Deeg, David E. Moller, Thomas A. Hardy
Journal: Diabetes Care
Diabetes Care 2016;39(11):e199–e200
https://doi.org/10.2337/dci16-0030
Published: 11 October 2016
View articletitled, Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249
Open the PDF for Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241–1249 in another window
Journal Articles

Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies

Christof M. Kazda, Ying Ding, Ronan P. Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E. Watson, Andrew J. Lewin, William H. Landschulz, Mark A. Deeg, David E. Moller, Thomas A. Hardy
Journal: Diabetes Care
Diabetes Care 2016;39(7):1241–1249
https://doi.org/10.2337/dc15-1643
Published: 17 December 2015
View articletitled, Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies
Open the PDF for Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies in another window
Includes: Supplementary data
Journal Articles

Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects

Robert R. Henry, Sunder Mudaliar, Theodore P. Ciaraldi, Debra A. Armstrong, Paivi Burke, Jeremy Pettus, Parag Garhyan, Siak Leng Choi, Scott J. Jacober, Mary Pat Knadler, Eric Chen Quin Lam, Melvin J. Prince, Namrata Bose, Niels Porksen, Vikram P. Sinha, Helle Linnebjerg
Journal: Diabetes Care
Diabetes Care 2014;37(9):2609–2615
https://doi.org/10.2337/dc14-0210
Published: 07 August 2014
View articletitled, Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects
Open the PDF for Basal Insulin Peglispro Demonstrates Preferential Hepatic Versus Peripheral Action Relative to Insulin Glargine in Healthy Subjects in another window
Includes: Supplementary data